EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor Longevity: a time-dependent biomarker of immune checkpoint inhibitor responsiveness across head and neck, lung, renal and urothelial cancers

Rebecca Romanò, Chiara Airoldi, Salvatore Alfieri, Anna Piemontese, Silvia Pierri, Gabriele Calvanese, Daniele Piscazzi, Gabriele Ciarlo, Diego Signorelli, Elio Gregory Pizzutilo, Giulio Cerea, Laura Giannetta und 13 weitere

The Oncologist · 06.11.2026

DOI: 10.1093/oncolo/oyag445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 06.11.2026. Verfasst von Rebecca Romanò und 24 weiteren Autor:innen. Beteiligte Einrichtung: Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background the duration of tumor persistence within the host–defined as Tumor Longevity (TL) – may capture cumulative biological and immunologic interactions, shaping immunotherapy treatment response. However, the impact of TL on outcomes with immune checkpoint inhibitors (ICI) remains unexplored. We hypothesized that TL may reflect integrated tumor-host dynamics influencing ICI efficacy and investigated this association in patients with head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), renal and urothelial cancer (R/UC). Materials and methods we conducted a retrospective, observational study including adult patients with advanced HNSCC, NSCLC, R/UC receiving ICI (≥first line) across 2 Italian cancer centers. TL, defined as the time from first histological diagnosis to ICI initiation, was analyzed as a continuous variable using 3-knot restricted cubic spline models. Multivariable logistic and Cox regression analyses assessed associations between TL and disease control rate (DCR), grade (G)≥3 immune-related adverse events (irAEs), and overall survival (OS).

Results

304 patients, diagnosed from 2002 to 2022, started ICI from 2014 to 2022. Median TL was 15.30 months (IQR 5.52-33.05). Overall DCR was 56.25% [95% CI 50.47; 61.91]; CTCAE G ≥ 3 irAEs occurred in 16 (5.2%) patients; 231 (76.0%) patients died. In multivariable analyses, longer TL was associated with higher DCR (OR Q3 vs. Q1 = 3.26; 95%CI 1.24; 8.59, p = 0.004), while no significant associations for G ≥ 3 irAEs (OR = 1.27; 95% CI 0.39–4.12) and OS (HR = 0.79; 95% CI 0.49–1.28; p = 0.407) were observed.

Conclusions

These real-world, hypothesis-raising results suggest that TL may capture clinically relevant information associated with ICI outcomes. TL may represent a pragmatic, time-dependent biomarker integrating tumor behavior and host factors. Prospective and translational studies incorporating TL with molecular and immune profiling are warranted to elucidate whether this association reflects tumor biology, host factors, treatment history, or their combination.

Schlagwörter

Stichwörter der Autor:innen

Immune checkpoint inhibitorsImmunotherapy responsePredictive biomarkersReal-world evidenceTumor longevity

Autor:innen und Institutionen

  • Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.
  • Department of Biostatistics for Clinical Research, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy.
  • Head and Neck Medical Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy.
  • IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
  • Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Zitieren

APA

Romanò, R., Airoldi, C., Alfieri, S., Piemontese, A., Pierri, S., Calvanese, G., Piscazzi, D., Ciarlo, G., Signorelli, D., Pizzutilo, E. G., Cerea, G., Giannetta, L., Zeppellini, A., Patelli, G., Buriolla, S., Rota, S., Manoni, F., Crippa, N., Silvestri, C., …, & Licitra, L. (2026). Tumor Longevity: a time-dependent biomarker of immune checkpoint inhibitor responsiveness across head and neck, lung, renal and urothelial cancers. The Oncologist. https://doi.org/10.1093/oncolo/oyag445

Vancouver

Romanò R, Airoldi C, Alfieri S, Piemontese A, Pierri S, Calvanese G, et al. Tumor Longevity: a time-dependent biomarker of immune checkpoint inhibitor responsiveness across head and neck, lung, renal and urothelial cancers. The Oncologist. 2026. doi:10.1093/oncolo/oyag445

BibTeX
@article{Roman2026,
  author = {Romanò, Rebecca and Airoldi, Chiara and Alfieri, Salvatore and Piemontese, Anna and Pierri, Silvia and Calvanese, Gabriele and Piscazzi, Daniele and Ciarlo, Gabriele and Signorelli, Diego and Pizzutilo, Elio Gregory and Cerea, Giulio and Giannetta, Laura and Zeppellini, Annalisa and Patelli, Giorgio and Buriolla, Silvia and Rota, Simone and Manoni, Federica and Crippa, Noemi and Silvestri, Cecilia and Oldani, Simone and Sangaletti, Sabina and Miceli, Rosalba and Sartore-Bianchi, Andrea and Siena, Salvatore and Licitra, Lisa},
  title = {Tumor Longevity: a time-dependent biomarker of immune checkpoint inhibitor responsiveness across head and neck, lung, renal and urothelial cancers},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag445}
}
Kostenlos starten →